THE detection of metastatic disease to bone is critical in the management of patients with cancer. Bone involvement by carcinoma is a fairly common postmortem finding, exceeded in frequency only by metastases to lymph nodes, lungs, and liver.1,2 The incidence of osseous metastases has been reported to be as high as 70% in some series of autopsies. This variance in reported incidence appears to depend on the thoroughness of the examination.3 In the tumors that commonly metastasize to bone (breast, prostate, thyroid, lung, and kidney), incidence of secondary bone involvement at the time of death may range from 50% to 85%.4,5 Both isotope and roentgenographic skeletal surveys are currently being used as means of achieving this detection.
Scan vs Roentgenogram: Physiological Bases of Visualization
There is general agreement that roentgenographic evidence of secondary malignant deposits in bone frequently appears late in the clinical course. While replacement of
O'Mara RE. Bone Scanning in Osseous Metastatic Disease. JAMA. 1974;229(14):1915–1917. doi:10.1001/jama.1974.03230520057039
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: